CMBI acted as Joint Bookrunner Joint Bookrunner and Joint Lead Manager for the Hong Kong IPO of Antengene Corporation Limited (6996.HK)

Transaction Overview

Antengene Corporation Limited (6996.HK).is successfully listed on the Hong Kong Stock Exchange on November 20, 2020. CMBI acted as Joint Bookrunner and Joint Lead Manager for this IPO.

Antengene is a clinical-stage Asia-Pacific (APAC) biopharmaceutical company focused on innovative oncology medicines. Antengene distinguishes itself through strong R&D capabilities and strategic approach to developing novel oncology therapies. Antengene is led by an experienced management team with a proven track record in developing and commercializing oncology drugs globally. The founder and CEO, Jay Mei, M.D., Ph.D., was a clinical research and development executive at Celgene. As of the Latest Practicable Date, Antengene had strategically designed and built a highly selective pipeline of 12 drug assets focused on oncology, including two late-stage clinical assets which Antengene in-licensed from Karyopharm and Celgene and are serving as Core Products, four early-stage clinical assets and six pre-clinical stage assets.

Antengene issued 154,153,500 shares (assuming the Over-allotment Option is not exercised) with offering price fixed at HK$18.08, and the offering size was approximately HK$2,787 million (assuming the Over-allotment Option is not exercised). The offering has received wide recognition from the market with the international tranche approximately 13.5 times oversubscribed. And HKPO tranche of Tigermed was 264.76 times oversubscribed.

As the joint bookrunner of this transaction, CMBI fully leveraged distribution network and introduced many high-quality orders. from International Long Only funds, Healthcare Specialist funds and top tier Chinese Long Only funds and insurance funds, perfectly demonstrating CMBI's broad investor coverage and strong underwriting capability.

The listing of Antengene is the 19th IPO from CMBI since 2019 in healthcare sector, and this transaction has once again demonstrated the leading position of CMBI in this sector.

Source: Prospectus and Company Announcement

About Antengene

Antengene is a clinical-stage Asia-Pacific (APAC) biopharmaceutical company focused on innovative oncology medicines. Antengene distinguishes itselves through strong R&D capabilities and strategic approach to developing novel oncology therapies. Antengene is led by an experienced management team with a proven track record in developing and commercializing oncology drugs globally. The founder and CEO, Jay Mei, M.D., Ph.D., was a clinical research and development executive at Celgene. As of the Latest Practicable Date, Antengene had strategically designed and built a highly selective pipeline of 12 drug assets focused on oncology, including two late-stage clinical assets which Antengene in-licensed from Karyopharm and Celgene and are serving as Core Products, four early-stage clinical assets and six pre-clinical stage assets.

Source: Prospectus

Disclaimer

This material is for reference only. Investor should rely only on the information contained in the Prospectus of this Global Offering to make investment decision.

Publish Date:2020-11-20
BackHome

Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong

Telephone: (852)3900 0888 Fax:(852)3761 8788

Copyright © 2019-2021 CMB International Capital Corporation Limited. All rights reserved.